This company recently went public with an IPO on Friday, October 16th 2026. They issued 11,111,111 shares at $17.00 - $19.00 per share. We will continue to update data for CTY as it becomes available. NASDAQ:CTY City Therapeutics (CTY) Stock Price, News & Analysis $20.77 0.00 (0.00%) As of 10/23/2026 04:00 PM Eastern Add Share Share Stock Analysis Stock AnalysisChartInsider TradesSEC Filings About City Therapeutics Stock (NASDAQ:CTY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get City Therapeutics alerts:Sign Up Key Stats Today's Range$20.03▼$21.1450-Day Range N/A52-Week Range$19.75▼$23.88Volume343,836 shsAverage Volume550,526 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview City Therapeutics is a biotechnology company focused on developing small RNA-based medicines. Its research is aimed at using RNA biology to regulate disease-related genes and address therapeutic targets that may be difficult to reach with conventional drug technologies. The company is developing a pipeline of RNA therapeutics for potential use across multiple disease areas. Its programs remain in development, and publicly available information does not indicate that City Therapeutics currently markets any approved products. Detailed information about the company’s historical development, geographic operations and leadership was not available from sufficiently reliable sources.AI Generated. May Contain Errors. Read More Receive CTY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for City Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CTY Stock News HeadlinesForget Anthropic: Biotech Is Quietly Dominating the IPO SphereOctober 24 at 4:00 PM | barrons.comCity Therapeutics (NASDAQ:CTY) Upgraded to "Hold" at Wall Street ZenOctober 24 at 1:15 AM | americanbankingnews.comDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monetary reset tied to executive order 14241 - one he says could draw a sharp dividing line between prepared investors and those left behind. The last time America reset its money - under Nixon in the 1970s - it produced an average of 1,300 new millionaires per day for over 50 years. Stansberry's new documentary names a core group of assets he believes are positioned to surge as Trump's new dollar rolls out. Watch Porter Stansberry's full briefing and get his three steps to prepare before December. | Porter & Company (Ad)City Therapeutics (NASDAQ:CTY) Stock: Insider Arch Venture Partners Xii, Llc Purchases 170,000 SharesOctober 21, 2026 | americanbankingnews.comCity Therapeutics (NASDAQ:CTY) Stock: Insider Robert Nelsen Purchases 170,000 SharesOctober 21, 2026 | americanbankingnews.comCity Therapeutics (NASDAQ:CTY) Major Shareholder Purchases 170,000 Shares of StockOctober 20, 2026 | insidertrades.comCity Therapeutics Announces Closing of $230.0 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesOctober 19, 2026 | globenewswire.comSee More Headlines CTY Stock Analysis - Frequently Asked Questions How have CTY shares performed this year? City Therapeutics' stock was trading at $22.40 on October 16, 2026. Since then, CTY shares have decreased by 7.3% and is now trading at $20.77. When did City Therapeutics IPO? City Therapeutics (CTY) raised $200 million in an IPO on Friday, October 16th 2026. The company issued 11,111,111 shares at $17.00-$19.00 per share. When does City Therapeutics' quiet period expire? City Therapeutics's quiet period expires on Wednesday, November 25th. City Therapeutics had issued 11,111,111 shares in its public offering on October 16th. The total size of the offering was $199,999,998 based on an initial share price of $18.00. During City Therapeutics' quiet period, underwriters and any insiders that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company. How do I buy shares of City Therapeutics? Shares of CTY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNASDAQ:CTY CIK2143850 Webwww.citytx.com Phone(857) 357-2024FaxN/AEmployees75Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableN/A BetaN/A 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:CTY) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding City Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share City Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
